Connect Biopharma Holdings Limited
CNTBNASDAQHealthcare● Active
$2.20
+$0.03(+1.38%)
Market Cap$138520477
P/E Ratio—
52W High$3.82
52W Low$0.753
Connect Biopharma Holdings Limited (CNTB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CNTB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.34
Est. -$0.29 · -17.2%
Revenue
$0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS
CNTB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.32 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.29 | -$0.34 | -17.2% | $0.00B | — | — |
| ▲ Q1 FY2026 | Mar 31, 2026 | -$0.30 | -$0.27 | +10.0% | — | $0.00B | — |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$0.22 | -$0.23 | -4.5% | $0.00B | — | — |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.27 | -$0.06 | +78.7% | $0.00B | — | — |
| ▲ Q3 FY2024 | Sep 5, 2024 | -$0.03 | $0.02 | +167.5% | $0.00B | $0.00B | +12.5% |
| ▼ Q2 FY2024 | Apr 16, 2024 | -$0.03 | -$0.07 | -131.7% | — | $0.00B | — |
| ▲ Q3 FY2023 | Sep 12, 2023 | -$6.92 | -$0.08 | +98.9% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.32
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.34
EPS Est.
-$0.29
EPS Surpr.
-17.2%
Revenue
$0.00B
Q1 FY2026
Mar 31, 2026Beat
EPS Actual
-$0.27
EPS Est.
-$0.30
EPS Surpr.
+10.0%
Revenue
—
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$0.23
EPS Est.
-$0.22
EPS Surpr.
-4.5%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.27
EPS Surpr.
+78.7%
Revenue
$0.00B
Q3 FY2024
Sep 5, 2024Beat
EPS Actual
$0.02
EPS Est.
-$0.03
EPS Surpr.
+167.5%
Revenue
$0.00B
Q2 FY2024
Apr 16, 2024Miss
EPS Actual
-$0.07
EPS Est.
-$0.03
EPS Surpr.
-131.7%
Revenue
—
Q3 FY2023
Sep 12, 2023Beat
EPS Actual
-$0.08
EPS Est.
-$6.92
EPS Surpr.
+98.9%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.25 | $-0.25 | $-0.25 | 2 |
| Q3 FY2027 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q2 FY2027 | $-0.29 | $-0.29 | $-0.29 | 2 |
| Q1 FY2027 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q4 FY2026 | $-0.38 | $-0.30 | $-0.19 | 6 |
| Q3 FY2026 | $-0.24 | $-0.24 | $-0.24 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -17.2% | $2.34 | $2.68 | +14.53% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +10.0% | $2.90 | $2.62 | -9.66% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -4.5% | $2.27 | $2.36 | +3.96% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +78.7% | $0.68 | $0.55 | -19.12% |
| ▲ Q3 FY2024 | Sep 5, 2024 | +167.5% | $1.29 | $1.19 | -7.75% |
| ▼ Q2 FY2024 | Apr 16, 2024 | -131.7% | $1.67 | $1.73 | +3.59% |
| ▲ Q3 FY2023 | Sep 12, 2023 | +98.9% | $0.78 | $0.76 | -2.82% |
| ▲ Q2 FY2023 | Apr 11, 2023 | +95.8% | $1.08 | $1.14 | +5.56% |
Q2 FY2026+14.53%
Report Date
May 12, 2026
EPS Beat/Miss
-17.2%
Price Before
$2.34
Price After
$2.68
Q1 FY2026-9.66%
Report Date
Mar 31, 2026
EPS Beat/Miss
+10.0%
Price Before
$2.90
Price After
$2.62
Q3 FY2025+3.96%
Report Date
Aug 13, 2025
EPS Beat/Miss
-4.5%
Price Before
$2.27
Price After
$2.36
Q1 FY2025-19.12%
Report Date
Mar 31, 2025
EPS Beat/Miss
+78.7%
Price Before
$0.68
Price After
$0.55
Q3 FY2024-7.75%
Report Date
Sep 5, 2024
EPS Beat/Miss
+167.5%
Price Before
$1.29
Price After
$1.19
Q2 FY2024+3.59%
Report Date
Apr 16, 2024
EPS Beat/Miss
-131.7%
Price Before
$1.67
Price After
$1.73
Q3 FY2023-2.82%
Report Date
Sep 12, 2023
EPS Beat/Miss
+98.9%
Price Before
$0.78
Price After
$0.76
Q2 FY2023+5.56%
Report Date
Apr 11, 2023
EPS Beat/Miss
+95.8%
Price Before
$1.08
Price After
$1.14
Avg Beat Reaction-6.76%
Avg Miss Reaction+7.36%
Beat Rate5 / 8 quarters
Largest Move-19.12% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CNTB ends December
Connect Biopharma Holdings Limited (CNTB) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.34 — missing the analyst consensus of $-0.29 by -17.2%. The next CNTB earnings date is expected around September 1, 2026.
Each quarter, investors track CNTB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CNTB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CNTB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CNTB earnings · 5 questionsConnect Biopharma Holdings Limited's next earnings report is expected around September 1, 2026. CNTB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CNTB historically reports after market close (AMC).
CNTB earnings datewhen is CNTB earningsCNTB next earnings datewhen does CNTB report earningsCNTB earnings calendar
▸ Source: FMP · Connect Biopharma Holdings Limited SEC filings · US GAAP · Connect Biopharma Holdings Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026